|
Market Data
Solventum Corporation
Solventum Corporation is a healthcare solutions provider focused on meeting crucial needs within the medical industry, both domestically and internationally. The company's core business revolves around three primary segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg division delivers a wide array of products, from advanced wound care and surgical supplies to sterilization assurance and temperature management tools. Solventum's Dental Solutions segment offers a comprehensive portfolio of dental and orthodontic products, while the Health Information Systems segment provides software and services designed to improve healthcare system efficiency. Solventum distributes its offerings through a multi-channel approach, including direct sales, distribution networks, and e-commerce platforms.
SOLV is currently trading at $69.10, giving Solventum Corporation a market cap of 11.97B and a P/E ratio of 7.7. Today's range spans $68.45–$69.55, with shares opening at $69.51 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 57/100.
Over the past year SOLV has traded between $62.38 and $88.20 - the current price is +10.8% off the 52-week low and -21.7% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $89.25 (range $71.00–$105.00), implying upside of +29.2%.
Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and SOLV (11.97B market cap) with a BUY read (82/100) and neutral sentiment (57/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 7.7. Price: $69.10 (in the lower half of its 52-week range in $62.38–$88.20). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.35 | - | - |
| Q4'25 | $1.53 | $1.57 | +2.9% |
| Q3'25 | $1.43 | $1.50 | +4.7% |
| Q2'25 | $1.45 | $1.69 | +16.3% |
| Q1'25 | $1.22 | $1.34 | +9.7% |
| Q4'24 | $1.31 | $1.41 | +7.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $2.0B | - | - |
| Q4'25 | $2.0B | $2.0B | -0.1% |
| Q3'25 | - | $2.1B | - |
| Q2'25 | - | $2.2B | - |
| Q1'25 | - | $2.1B | - |
| Q4'24 | - | $2.1B | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).